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The use of immune checkpoint inhibitors is becoming more commonplace in clinical trials across the nation.
Two important factors in the tumour-immune response are the checkpoint protein programmed death-1 (PD-
1) and its ligand PD-L1. We propose a mathematical tumour-immune model using a system of ordinary
differential equations to study dynamics with and without the use of anti-PD-1. A sensitivity analysis is
conducted, and series of simulations are performed to investigate the effects of intermittent and continuous
treatments on the tumour-immune dynamics. We consider the system without the anti-PD-1 drug to conduct
a mathematical analysis to determine the stability of the tumour-free and tumorous equilibria. Through sim-
ulations, we found that a normally functioning immune system may control tumour. We observe treatment
with anti-PD-1 alone may not be sufficient to eradicate tumour cells. Therefore, it may be beneficial to
combine single agent treatments with additional therapies to obtain a better antitumour response
